CORPORATE MEDIA RELEASE
ENDOSCOPY PUBLISHES THE DAYB PHASE III TRIAL FOR PLENVU® (NER1006), THE FIRST ONE LITRE PEG BOWEL PREPARATION[i]
AMSTERDAM. The Netherlands, 24 July 2018, 18:00 CET. Norgine B.V. today announced that results from the PLENVU® Phase III DAYB trial were published in ENDOSCOPY, a monthly peer-reviewed medical journal on behalf of the European Society of Gastrointestinal Endoscopy.
The DAYB study is a European study that compared PLENVU® to a sodium picosulfate and magnesium salt solution using a 1-Day before split-dosing regimen in adults. The study met both primary endpoints.
Colonoscopy is an effective method for colorectal cancer screening and has been shown to reduce both the incidence and mortality of colorectal cancer when applied in the general population. Inadequate precolonoscopy bowel cleansing reduces the diagnostic accuracy of colonoscopy, particularly for the detection of smaller lesions and sessile polyps. This may result in repeat procedures, thereby increasing costs and potentially delaying the initiation of treatment, and potentially increasing resource requirement.[iii],[iv],[v]
PLENVU® is approved in Europe and in the US. In Europe, PLENVU® is available through Norgine and in the US through its partner Salix Pharmaceuticals, Ltd. (“Salix”), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc.
Norgine manufactures PLENVU® globally.
* One side lower confidence limit
Notes to Editors:
About Norgine
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.
Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
PLENVU is a trademark of the Norgine group of companies.
Media Contact :
Isabelle Jouin, T: +44 (0)1895 826237
Follow us @norgine
References
i. Schreiber Stefan et al. Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial. Endoscopy 2019; 51: 1–16
https://doi.org/10.1055/a-0639-5070
[ii] Clark B. et al. Yield of repeat forward-view examination of the right side of the colon in screening and surveillance colonoscopy. Gastrointest endosc 2016;(84(1): 126-132
[iii] Bechtold ML, Mir F, Puli SR et al. Optimizing bowel preparation for colonoscopy: a guide to enhance quality of visualization. Ann Gastroenterol 2016; 29: 137 – 146
[iv] Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014; 348: g2467
[v] Baxter NN, Warren JL, Barrett MJ et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol 2012; 30: 2664 – 2669
Sitios web de Norgine
Contáctenos